Kora Healthcare acquires BFK Pharma and establishes new pharma subsidiary in Germany
Dublin Ireland – 10th March 2026 Kora Healthcare is delighted to announce the acquisition of BFK-Pharma GmbH with offices in Lüneburg and Neurruppin, its first company acquisition in Germany. Following the acquisition, BFK-Pharma GmbH shall be re-branded as Kora Healthcare Deutschland GmbH, a wholly owned subsidiary of Kora Corporation Limited, trading as Kora Healthcare. This acquisition provides a ready-to-market Germany subsidiary that will promote and market Kora Healthcare’s well-established portfolio of pharmaceutical products and provides a new platform for growth in Germany for Kora Healthcare’s evolving product pipeline. This acquisition comes on the foot of Kora Healthcare’s acquisitions in 2022 and 2023 of a number of medicinal marketing authorisations in Germany.
Importantly, through this acquisition, Kora Healthcare Deutschland acquires a German Wholesale Distribution Authorisation (WDA) allowing for Kora Healthcare Deutschland GmbH to import, supply and export into the wider healthcare system across Germany, specifically hospitals. This acquisition also sees Dr. Dirk Bremen appointed as the Commercial Manager (DE) and Responsible Person for Kora Healthcare Germany GmbH.
Commenting on the acquisition, Kora Healthcare CEO, Conor O’Daly, noted “this acquisition not only provides a ready-made commercial platform to further develop our current and future German portfolio, but fast-tracks our evolving European presence and our focus on serving patient cohorts with unmet needs across niche diseases and indications”.
END
About Kora Healthcare
Kora Healthcare is an emerging company committed to identifying, developing and commercialising healthcare products internationally across a spectrum of therapeutic areas. Our present patient and therapeutic focus are across Supportive Care: medicines that treat or manage secondary conditions arising from, relating to and complicated by underlying serious, chronic and long-term diseases, and genito-urinary medicine: medicines that treat or manage conditions related to sexual and reproductive health in both women and men.
For further information please contact:
Aoife O’Daly, Business Support & Sustainability Lead
+353 (0)1890406
